ATHA — Athira Pharma Income Statement
0.000.00%
Last trade - 00:00
- $81.64m
- -$65.78m
- 11
- 43
- 75
- 39
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 5.45 | 19.8 | 64 | 104 | 125 |
Operating Profit | -5.45 | -19.8 | -64 | -104 | -125 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.16 | -20 | -54.9 | -95.6 | -118 |
Net Income After Taxes | -5.16 | -20 | -54.9 | -95.6 | -118 |
Net Income Before Extraordinary Items | |||||
Net Income | -5.16 | -20 | -54.9 | -95.6 | -118 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -5.16 | -20 | -54.9 | -95.6 | -118 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.167 | -0.62 | -1.49 | -2.27 | -3.14 |
Dividends per Share |